CSF3R,G-CSF-R: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD

It's the GeneMedi's summary page for Target/Biomarker Introduction of G-CSF-R,CSF3R. The page also collects GeneMedi's different modalities and formats products for G-CSF-R in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the G-CSF-R target is also connected to human indications/diseases/conditions/MOA.

Target sublocation: Transmembrane Protein.

The protein encoded by this gene is the receptor for colony stimulating factor 3, a cytokine that controls the production, differentiation, and function of granulocytes. The encoded protein, which is a member of the family of cytokine receptors, may also function in some cell surface adhesion or recognition processes. Alternatively spliced transcript variants have been described. Mutations in this gene are a cause of Kostmann syndrome, also known as severe congenital neutropenia. [provided by RefSeq, Aug 2010]

Pre-made G-CSF-R-specific INN-index biosimilar (antibody&conjugates)-eflapegrastim, efbemalenograstim alfa, filgrastim, balugrastim, Anumigilimab, pegfilgrastim

Anti-G-CSF-R therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Cat No.	Products Name (INN Index)	INN Name	Previous Name	Target	Format	Order
GMP-Bios-INN-818		eflapegrastim		CSF3R	pegylated
GMP-Bios-INN-812	Pre-Made Efbemalenograstim Alfa Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with human IGHG2 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting CD114/GCSFR/SCN7	efbemalenograstim alfa		CSF3R/G-CSF-R	Fusion Protein
GMP-Bios-INN-852	Pre-Made Filgrastim Biosimilar, Recombinant Protein targeting CSF3R: Recombinant therapeutic protein targeting CD114/GCSFR/SCN7	filgrastim		CSF3R/G-CSF-R	Recombinant Protein
GMP-Bios-INN-748	Pre-Made Balugrastim Biosimilar, Fusion Protein targeting CSF3R/G-CSF-R fused with ALB (albumin, human serum albumin, HSA): Recombinant therapeutic protein targeting CD114/GCSFR/SCN7	balugrastim		CSF3R/G-CSF-R	Fusion Protein
GMP-Bios-ab-655	Pre-Made Anumigilimab biosimilar, Whole mAb, Anti-CSF3R/G-CSF-R Antibody: Anti-CD114/GCSFR/SCN7 therapeutic antibody	Anumigilimab		CSF3R/G-CSF-R	Whole mAb
GMP-Bios-INN-951		pegfilgrastim		CSF3R	pegylated

Pre-made anti-G-CSF-R inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research

Pre-made anti-G-CSF-R benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-G-CSF-R mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Cat No.	Antibody Name	Format	Classified by tag	Order
GM-Tg-hg-T98913-Ab	Anti-G-CSF-R/CSF3R monoclonal antibody	mab	Biofunctional antibody, Therapeutics Target antibody